US generic drugmaker Perrigo has agreed to buy Irish firm Elan for just under 6.5 billion euros.
The deal gives it tax savings from being domiciled in Ireland.
By moving its headquarters, Perrigo can take advantage of the very low 12.5 percent corporate tax rate in Ireland compared with 35 percent in the United States.
...
http://www.euronews.net/